Yesterday, Jan. 14, 2016, 33 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $925.00 to $5,000,000.00.

Highlighted Stocks Traded by Insiders:

Ruby Tuesday (RT) - FREE Research Report

Clayton Kevin T, who is Director at Ruby Tuesday, bought 30,000 shares at $5.25 on Jan. 14, 2016. Following this transaction, the Director owned 178,244 shares meaning that the stake was boosted by 20.24% with the 30,000-share transaction.

Buettgen James J, who is President & Chief Exec Officer at Ruby Tuesday, bought 20,000 shares at $5.11 on Jan. 14, 2016. Following this transaction, the President & Chief Exec Officer owned 793,109 shares meaning that the stake was boosted by 2.59% with the 20,000-share transaction.

The shares most recently traded at $5.33, up $0.22, or 4.16% since the insider transaction. Historical insider transactions for Ruby Tuesday go as follows:

  • 4-Week # shares bought: 40,000
  • 4-Week # shares sold: 8,075
  • 12-Week # shares bought: 60,000
  • 12-Week # shares sold: 8,075
  • 24-Week # shares bought: 60,000
  • 24-Week # shares sold: 8,075

The average volume for Ruby Tuesday has been 387,800 shares per day over the past 30 days. Ruby Tuesday has a market cap of $317.7 million and is part of the services sector and leisure industry. Shares are down 0.73% year-to-date as of the close of trading on Thursday.

Ruby Tuesday, Inc., together with its subsidiaries, engages in the ownership, development, operation, and franchise of casual dining restaurants in the United States and internationally. Currently, there are no analysts who rate Ruby Tuesday a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RT - FREE

TheStreet Quant Ratings rates Ruby Tuesday as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full Ruby Tuesday Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Village Super Market (VLGEA) - FREE Research Report

Estate of Perry Sumas, who is Shareholder at Village Super Market, sold 6,402 shares at $24.92 on Jan. 14, 2016. Following this transaction, the Shareholder owned 735,338 shares meaning that the stake was reduced by 0.86% with the 6,402-share transaction.

The shares most recently traded at $24.37, down $0.55, or 2.25% since the insider transaction. Historical insider transactions for Village Super Market go as follows:

  • 4-Week # shares sold: 14,043
  • 12-Week # shares sold: 64,680
  • 24-Week # shares sold: 159,783

The average volume for Village Super Market has been 26,100 shares per day over the past 30 days. Village Super Market has a market cap of $245.2 million and is part of the services sector and retail industry. Shares are down 5.54% year-to-date as of the close of trading on Thursday.

Village Super Market, Inc. operates a chain of supermarkets in the United States. Its stores feature specialty departments, such as onsite bakery, an expanded delicatessen, natural and organic foods, ethnic and international foods, prepared foods, and pharmacies. The stock currently has a dividend yield of 4.01%. The company has a P/E ratio of 11.3. Currently, there are no analysts who rate Village Super Market a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VLGEA - FREE

TheStreet Quant Ratings rates Village Super Market as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, attractive valuation levels and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Village Super Market Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Cozadd Bruce C, who is Chairman & CEO at Jazz Pharmaceuticals, sold 2,500 shares at $123.81 on Jan. 14, 2016. Following this transaction, the Chairman & CEO owned 284,396 shares meaning that the stake was reduced by 0.87% with the 2,500-share transaction.

The shares most recently traded at $122.87, down $0.94, or 0.77% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 100
  • 12-Week # shares sold: 36,413
  • 24-Week # shares sold: 52,513

The average volume for Jazz Pharmaceuticals has been 699,000 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $7.6 billion and is part of the health care sector and drugs industry. Shares are down 10.01% year-to-date as of the close of trading on Thursday.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 23.5. Currently, there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.